How should hypercalcemia be evaluated and managed, including severity classification, initial work‑up, and treatment options?

Hypercalcemia: Evaluation and Management

Severity Classification

Classify hypercalcemia severity immediately to guide urgency of intervention: mild (10–11 mg/dL), moderate (11–12 mg/dL), or severe (>14 mg/dL). 1, 2 Ionized calcium thresholds are: mild 5.6–8.0 mg/dL (1.4–2 mmol/L), severe ≥10 mg/dL (≥2.5 mmol/L). 3

• Mild hypercalcemia is usually asymptomatic but may cause fatigue and constipation in ~20% of patients. 3
• Moderate hypercalcemia presents with polyuria, polydipsia, nausea, confusion, vomiting, and abdominal pain. 1, 2
• Severe hypercalcemia causes mental status changes, dehydration, bradycardia, hypotension, acute renal failure, somnolence, and coma. 2, 3

---

Initial Diagnostic Work-Up

Essential Laboratory Panel

Measure intact parathyroid hormone (iPTH) first—this single test distinguishes PTH-dependent from PTH-independent causes and is the most important initial diagnostic step. 1, 3

• If iPTH is elevated or inappropriately normal (in the setting of hypercalcemia), diagnose primary hyperparathyroidism (PHPT). 1, 4
• If iPTH is suppressed (<20 pg/mL), pursue PTH-independent causes (malignancy, vitamin D disorders, medications). 1, 3

Complete the initial panel with: 5, 1, 2

• Serum calcium (total and ionized), albumin, phosphorus, magnesium
• Creatinine and BUN (assess renal function)
• PTHrP (if iPTH suppressed—elevated in most malignancy-associated hypercalcemia)
• 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D (measure both together for diagnostic accuracy in granulomatous disease, lymphoma, vitamin D intoxication) 5, 1

Calculate corrected calcium using: Corrected calcium (mg/dL) = Total calcium + 0.8 × [4.0 – Serum albumin (g/dL)]. 5, 1, 2 However, measure ionized calcium directly whenever possible to avoid pseudo-hypercalcemia from hemolysis or improper sampling. 5, 1

Medication and Supplement History

Obtain detailed history of: 5

• Thiazide diuretics, lithium (both cause hypercalcemia) 1, 4
• Calcium supplements (>500 mg/day), vitamin D (>400 IU/day), vitamin A
• Calcitriol, paricalcitol (cause hypercalcemia in 22.6–43.3% of patients) 5
• Patiromer (calcium-sorbitol counterion exchanges calcium for potassium) 5

Etiology-Specific Patterns

Primary hyperparathyroidism: 1, 4

• Elevated or inappropriately normal iPTH
• Hypophosphatemia
• Hyperchloremic metabolic acidosis
• Kidney stones (never seen in malignancy)
• Chronic course (>6 months), lower calcium (<12 mg/dL)
• No anemia

Malignancy-associated hypercalcemia: 1, 4

• Suppressed iPTH, elevated PTHrP
• Rapid onset (days to weeks), higher calcium (often >12 mg/dL)
• Marked anemia
• No kidney stones, no metabolic acidosis

Vitamin D–mediated hypercalcemia (granulomatous disease, lymphoma): 5, 1

• Suppressed iPTH
• Elevated 1,25-dihydroxyvitamin D (extrarenal 1α-hydroxylase in activated macrophages)
• In sarcoidosis, ~6% develop hypercalcemia; of these, 84% have low 25-OH vitamin D, 11% have elevated 1,25-(OH)₂ vitamin D 5

Vitamin D intoxication: 1

• Elevated 25-hydroxyvitamin D

---

Treatment Algorithm

Step 1: Immediate Stabilization (All Moderate-to-Severe Cases)

Initiate aggressive IV normal saline hydration immediately—target urine output 100–150 mL/hour (3 mL/kg/hour in children <10 kg) to correct hypovolemia and promote calciuresis. 5, 1, 2 Volume contraction and calcium-induced renal injury are critical drivers of severe hypercalcemia. 6

• Administer 250–500 mL crystalloid boluses every 15 minutes until rehydration is achieved, then maintain diuresis >2.5 L/day in adults. 5
• Balanced crystalloids are preferred over 0.9% saline to avoid hyperchloremic metabolic acidosis with large volumes. 5
• Monitor serum calcium, creatinine, and electrolytes (potassium, magnesium, phosphorus) every 6–12 hours during the acute phase. 5

Loop diuretics (furosemide) should be used ONLY after complete volume repletion and ONLY in patients with renal or cardiac insufficiency to prevent fluid overload. 5, 1, 2, 4 Premature use worsens dehydration and hypercalcemia. 5

Discontinue immediately: 5, 2

• All calcium supplements and calcium-based phosphate binders
• All vitamin D supplements (even if 25-OH vitamin D is low)
• Vitamin D analogs (calcitriol, paricalcitol)
• Nephrotoxic agents (NSAIDs, iodinated contrast, aminoglycosides) 5

Step 2: Definitive Pharmacologic Treatment

Bisphosphonates (First-Line for Moderate-to-Severe Hypercalcemia)

Administer zoledronic acid 4 mg IV infused over ≥15 minutes as the preferred bisphosphonate—it is superior to pamidronate, normalizing calcium in ~50% of patients by day 4. 5, 1, 2, 3 Bisphosphonates can be initiated early without waiting for complete rehydration. 5

• Dose adjustments for renal impairment: Reduce dose if creatinine clearance <60 mL/min. 5
• Check serum creatinine before each dose; withhold if renal function deteriorates (increase >0.5 mg/dL from normal baseline or >1.0 mg/dL from abnormal baseline). 5, 1
• Pamidronate 90 mg IV over 2 hours is an alternative if zoledronic acid is unavailable. 5
• Correct hypocalcemia before initiating bisphosphonates and provide oral calcium 500 mg plus vitamin D 400 IU daily during treatment to prevent hypocalcemia. 5
• Baseline dental examination is mandatory before starting bisphosphonates to prevent osteonecrosis of the jaw (ONJ). 5
• Continue bisphosphonate therapy for up to 2 years in patients with multiple myeloma or bone metastases. 5

Denosumab (Refractory or Renal Impairment)

Use denosumab 120 mg subcutaneously for bisphosphonate-refractory hypercalcemia or in patients with impaired renal function (CrCl <60 mL/min or GFR ≤20 mL/min). 5, 1, 2, 3 Denosumab lowers calcium in 64% of patients within 10 days and has lower renal toxicity than bisphosphonates but higher risk of hypocalcemia. 5

Calcitonin (Bridge Therapy)

Administer calcitonin-salmon 100 IU subcutaneously or intramuscularly every 12 hours for immediate short-term management of severe symptomatic hypercalcemia while waiting for bisphosphonates to take effect. 5, 1, 2, 4 Calcitonin lowers calcium within hours but has limited efficacy (1–4 hours) and tachyphylaxis develops. 5, 6

Corticosteroids (Vitamin D–Mediated Hypercalcemia)

Corticosteroids are the primary treatment for hypercalcemia due to excessive intestinal calcium absorption: vitamin D intoxication, granulomatous diseases (sarcoidosis, tuberculosis), lymphomas, and multiple myeloma. 5, 1, 2, 3

• Prednisone 20–40 mg/day orally or methylprednisolone IV equivalent. 5
• Allow 3–6 months to demonstrate responsiveness before escalating. 5
• Target the lowest effective dose ≤10 mg/day; if unable to wean below 10 mg/day after 3–6 months, add methotrexate as a steroid-sparing agent. 5
• Corticosteroids are NOT indicated for solid-tumor malignancies (e.g., spindle-cell carcinoma). 5

Mandatory monitoring with corticosteroids: 5

• Pneumocystis pneumonia prophylaxis if ≥20 mg methylprednisolone equivalent for ≥4 weeks
• GI prophylaxis with proton pump inhibitor
• Tuberculosis screening (T-spot) before initiating in granulomatous disease
• Calcium and vitamin D supplementation (paradoxically needed for bone loss prevention, but carefully monitored)

Step 3: Renal Replacement Therapy (Severe Refractory Cases)

Initiate hemodialysis with calcium-free or low-calcium dialysate (1.25–1.50 mmol/L or 1.5–2.0 mEq/L) for severe hypercalcemia complicated by renal insufficiency, oliguria, or when pharmacologic measures fail. 5, 1, 2, 4, 3 Bisphosphonates are contraindicated when GFR ≤20 mL/min due to risk of irreversible renal failure. 5

---

Cause-Specific Definitive Management

Primary Hyperparathyroidism

Parathyroidectomy is indicated for: 1, 2

• Symptomatic disease
• Age <50 years
• Calcium >0.25 mmol/L (>1 mg/dL) above upper normal limit
• Osteoporosis, impaired kidney function, kidney stones, or hypercalciuria

Observation with monitoring is appropriate for patients >50 years with calcium <1 mg/dL above upper limit and no skeletal or kidney disease. 3

Tertiary Hyperparathyroidism (CKD/Post-Transplant)

Consider parathyroidectomy for persistent hypercalcemic hyperparathyroidism (iPTH >800 pg/mL) despite optimized medical therapy. 5 Persistent autonomous PTH secretion after transplantation increases graft failure and all-cause mortality. 5

Malignancy-Associated Hypercalcemia

Treat the underlying cancer when possible—this is essential for long-term control. 5, 1, 2 Hypercalcemia of malignancy carries a poor prognosis with median survival ~1 month. 5

• For multiple myeloma: Hydration, zoledronic acid 4 mg IV, corticosteroids, and/or calcitonin. 5 Continue bisphosphonates for up to 2 years. 5
• Plasmapheresis is adjunctive therapy for symptomatic hyperviscosity in multiple myeloma. 5

---

Monitoring Strategy

Acute phase (first 48–72 hours): 5

• Ionized calcium every 4–6 hours, then twice daily until stable
• Serum creatinine, electrolytes (K, Mg, PO₄) every 6–12 hours
• Urine output continuously

Target corrected calcium 8.4–9.5 mg/dL (preferably lower end of range). 5 Keep calcium-phosphorus product <55 mg²/dL² to prevent soft-tissue calcification. 5

Long-term monitoring: 1, 2

• Serum calcium, renal function, electrolytes regularly
• Watch for bisphosphonate complications: renal toxicity, ONJ
• Asymptomatic hypocalcemia post-treatment does not require intervention; treat only symptomatic hypocalcemia (tetany, seizures) with calcium gluconate 50–100 mg/kg 5

---

Critical Pitfalls to Avoid

• Do not delay bisphosphonate therapy in moderate-to-severe hypercalcemia; temporary measures (calcitonin, insulin, beta-agonists) provide only 1–4 hours of benefit. 5
• Do not use loop diuretics before complete volume repletion—this worsens hypercalcemia. 5, 4
• Do not rely on corrected calcium alone—measure ionized calcium to avoid pseudo-hypercalcemia. 5, 1
• Do not use bisphosphonates when GFR ≤20 mL/min—use denosumab or dialysis instead. 5
• Do not use corticosteroids for solid-tumor malignancies—they are ineffective. 5
• Do not restrict calcium intake excessively without supervision—this worsens bone disease. 5
• Avoid NSAIDs and IV contrast in renal impairment—they worsen kidney function. 5, 2

5, 1, 2, 4, 7, 3, 6, 8